<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04114461</url>
  </required_header>
  <id_info>
    <org_study_id>HL-TOF-101</org_study_id>
    <nct_id>NCT04114461</nct_id>
  </id_info>
  <brief_title>Study to Evaluate HL-TOF Tab. 5 mg Compared With XelJanz Tab. in Healthy Volunteers</brief_title>
  <official_title>An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and Pharmacokinetics of HL-TOF Tab. 5 mg Compared With Those of XelJanz Tab. in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and pharmacokinetics of HL-TOF tab. 5 mg compared with those of
      XelJanz tab. in healthy volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety and pharmacokinetics of tofacitinib after
      single oral administration of Xeljanz tab. 5mg as reference drug and HL-TOF tab. 5mg as test
      drug in healthy voluteers. AUC and Cmax would be evaluated for the pharmacokinetics. Adverse
      event, Laboratory examination and other examination result would be evaluated for the safety.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 6, 2019</start_date>
  <completion_date type="Actual">December 4, 2019</completion_date>
  <primary_completion_date type="Actual">December 4, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>2X2</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0 hour, 0.17 hour, 0.34 hour, 0.5 hour, 0.67 hour, 0.83 hour, 1 hour, 1.5 hour, 2 hour, 3 hour, 4 hour, 6 hour, 9 hour, 12 hour</time_frame>
    <description>Maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>0 hour, 0.17 hour, 0.34 hour, 0.5 hour, 0.67 hour, 0.83 hour, 1 hour, 1.5 hour, 2 hour, 3 hour, 4 hour, 6 hour, 9 hour, 12 hour</time_frame>
    <description>Area under curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>0 hour, 0.17 hour, 0.34 hour, 0.5 hour, 0.67 hour, 0.83 hour, 1 hour, 1.5 hour, 2 hour, 3 hour, 4 hour, 6 hour, 9 hour, 12 hour</time_frame>
    <description>Number of participants with adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>HL-TOF tab. 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tofacitinib freebase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xeljanz tab. 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tofacitinib citrate (5mg as tofacitinib)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HL-TOF tab. 5mg</intervention_name>
    <description>HL-TOF</description>
    <arm_group_label>HL-TOF tab. 5mg</arm_group_label>
    <other_name>Tofacitinib freebase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xeljanz tab. 5mg</intervention_name>
    <description>Xeljanz</description>
    <arm_group_label>Xeljanz tab. 5mg</arm_group_label>
    <other_name>Tofacitinib citrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Years 19-60

          -  No pathological symptoms or findings

          -  Suitable for the criteria for examination

          -  90≤SBP≤139, 60≤DBP≤89

          -  Body weight≥50kg (Female≥45kg) and 18≤BMI≤30kg/m2

          -  Contraceptive during the study period

          -  Volunteer for the study and sign to ICF

        Exclusion Criteria:

          -  Subject with medical history which affect on the absorption of drug

          -  Following condition: Mental illness, Hepatic disorder, Tuberculosis, ANC&lt;
             500cells/mm3, ALC&lt;500cells/mm3, Hb&lt;8g/dL

          -  Subject with hypersensitivity reaction to HL-TOF and Xeljanz

          -  Subject with galactose intolerance, Lapp lactase deficiency, glucose-galactose
             malabsorption

          -  Subject who take a vaccination within 30 days

          -  Subject who take a medication such as barbiturates within 30 days

          -  Subject who take a medication that affect to the pharmacokinetics of drug within 10
             days

          -  Subject who take alcohol more than 21 cups per week

          -  Subject who smoke 20 cigarettes per day

          -  Subject who participate in any clinical investigation within 6 month prior to study
             medication dosing

          -  Subject with whole blood donation within 60 days, component blood donation within 14
             days, blood donation within 30 days

          -  Subject with decision of non-participation through investigator's review
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JAEWOO KIM</last_name>
    <role>Principal Investigator</role>
    <affiliation>H Plus Yangji Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>YANGJI Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 2, 2019</study_first_submitted>
  <study_first_submitted_qc>October 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2019</study_first_posted>
  <last_update_submitted>May 10, 2020</last_update_submitted>
  <last_update_submitted_qc>May 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

